pancreatic-ductal-adenocarcinoma

Documents about pancreatic-ductal-adenocarcinoma

• Repurposing Rilmenidine as a Potential Antimetastatic Therapy Targeting Nischarin in Pancreatic Ductal Adenocarcinoma#356119Zenodo (CERN)
• Impact of Multidisciplinary and Radiologic Review on Outcome of Pancreatic Cancer Patients: an Observational Study#871485ClinicalTrials.gov
• Metabolic plasticity in pancreatic ductal adenocarcinoma progression and response to treatment.#25624NCBI PubMed Central
• Panuri Performance Study#805849ClinicalTrials.gov
• Study of NAC of GA Therapy for Patients With BRPC#966768ClinicalTrials.gov
• Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer#917677ClinicalTrials.gov
• A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy#908639ClinicalTrials.gov
• A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer#805484ClinicalTrials.gov
• Clinical Study Between Robotic and Open Surgery in Patients With Pancreatic Cancer#813430ClinicalTrials.gov
• Pilot Study of a Multimodal Prehabilitation Pancreatic Cancer Program#859811ClinicalTrials.gov
• Organochlorine Concentration in Adipose Tissue and Pancreatic Adenocarcinoma#881472ClinicalTrials.gov
• KRAS-driven cytokine-metabolic crosstalk shapes immune exclusion in pancreatic ductal adenocarcinoma.#666137NCBI PubMed Central
• NALIRIFOX as Induction Therapy in LAPC#980010ClinicalTrials.gov
• Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases#903841ClinicalTrials.gov
• Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery#623556ClinicalTrials.gov
• Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer#158235ClinicalTrials.gov
• Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer#846233ClinicalTrials.gov
• IBI343 in Combination Therapy for Advanced Malignant Solid Tumors#830064ClinicalTrials.gov
• Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma#1033649ClinicalTrials.gov
• Fingerprinting the Metabolic and Lipidomic Landscapes of Pancreatic Ductal Adenocarcinoma with MALDI Imaging.#227798NCBI PubMed Central
• UCSF PANC Cyst Registry#1008846ClinicalTrials.gov
• OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas#830751ClinicalTrials.gov
• Prognosis Prediction Model After Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma: A Multicenter Study (OS-HBP-2)#345333OKAYAMA UNIVERSITY SCIENTIFIC ACHIEVEMENT REPOSITORY
• Oncologic Impact of Splenectomy-omitting Radical Pancreatectomy in Well-selected Left-sided Pancreatic Cancer#828719ClinicalTrials.gov
• The Canopy Cancer Collective Clinical Registry Protocol#839204ClinicalTrials.gov
• DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer#878001ClinicalTrials.gov
• Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma#955573Koc University Digital Collections
• Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance#898032ClinicalTrials.gov
• A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors#1008188ClinicalTrials.gov
• MSCAN: ctDNA Methylation as Prognostic and Theranostic Tool for Pancreatic Cancer#885046ClinicalTrials.gov
• Polymorphic variants within non-coding RNA and risk of pancreatic ductal adenocarcinoma#260095IRIS
• The CD49b (ITGA2) collagen receptor excludes CD8(+) T cell infiltration in pancreatic ductal adenocarcinoma.#334824NCBI PubMed Central
• Citrulline and Faecal Elastase 1 as a Combined Diagnostic Biomarker for Pancreatic Ductal Adenocarcinoma#451900Europe PMC
• Prevalence of new onset diabetes mellitus among patients with pancreatic ductal adenocarcinoma: a population-based study#668753bioRxiv / medRxiv
• Hepatic Artery Chemotherapy for Patients With Localized Pancreas Cancer#805269ClinicalTrials.gov
• Radiomics based on multiphasic contrast-enhanced CT combined with clinical features for differentiating hypovascular pancreatic neuroendocrine tumors and pancreatic ductal adenocarcinoma.#135748NCBI PubMed Central
• Efficacy of Chemopreventive Agents on Disease-free and Overall Survival in Patients With Pancreatic Ductal Adenocarcinoma: The CAOS Study#160313ClinicalTrials.gov
• The Practices of Pancreatic Neck Margin Testing and Their Outcomes after Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma#341610Springer Nature OA
• Conditional knockout of hypoxia-inducible factor 1-alpha in tumor-infiltrating neutrophils protects against pancreatic ductal adenocarcinoma#379949DR-NTU (Digital Repository of NTU)
• Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer#398318ClinicalTrials.gov
• Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma#825682ClinicalTrials.gov
• Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors#839349ClinicalTrials.gov
• PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP)#886025ClinicalTrials.gov
• Predictive Nomogram for Recurrence After Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma: A Multicenter Study (OS-HBP-2)#345337OKAYAMA UNIVERSITY SCIENTIFIC ACHIEVEMENT REPOSITORY
• Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies#851709ClinicalTrials.gov
• Selective Plasma Adsorption of Extracellular DNA in Prevention of Intraoperative Metastasis in Pancreatic Cancer (Pilot Study)#979284ClinicalTrials.gov
• Computed tomography quantitative imaging features for pancreatic ductal adenocarcinoma after neoadjuvant therapy: a narrative review.#452948NCBI PubMed Central
• Study of Bevacizumab in Combination With 5-FU, Oxaliplatin and External Beam Radiation Followed by Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer#911311ClinicalTrials.gov
• ASO-based PKM splice-switching therapy increases anti-CTLA-4 antibody efficacy in pancreatic ductal adenocarcinoma#125805Europe PMC
• Suppression of endothelial cell FAK expression reduces pancreatic ductal adenocarcinoma metastasis after gemcitabine treatment#291412Gestión del Repositorio Documental de la Universidad de Salamanca